[Skip to Content]

Upstate Active Clinical Trials

Study Title:

S1500: A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors, Crizotinib, Savolitinibm and Sunitinib in Metastatic Papillary Renal Carcinoma

What is the purpose of the study?

This randomized phase II trial studies how well cabozantinib-s-malate, crizotinib, volitinib, or sunitinib malate work in treating patients with kidney cancer that has spread from where it started to nearby tissue or lymph nodes or to other places in the body. Cabozantinib-s-malate, crizotinib, volitinib, and sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Upstate Institutional Review Board (IRB) Number:

921506

Study/Protocol ID:

S1500

Study Phase:

II

Patient Age Group:

Adults

Principal Investigator:

Sam Benjamin, MD

Where will the study take place?

Upstate Cancer Center - All procedures
Oneida - All procedures
Oswego - All procedures

ClinicalTrials.Gov ID:

NCT02761057

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Alexandra Koulouris, BA
Phone: 315-464-8237
Email: kouloura@upstate.edu

Return to Previous Page || Search Again

Top